| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SQ 22536 | 17318-31-9 | sc-201572 sc-201572A | 5 mg 25 mg | $95.00 $363.00 | 13 | |
SQ 22,536 acts as an adenylyl cyclase inhibitor, thereby reducing cAMP levels. Since OR2A12 is a G protein-coupled receptor that signals via cAMP, this compound indirectly leads to the decreased activity of OR2A12 by limiting its downstream signaling. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 inhibits CaMKII, which is indirectly involved in OR2A12 signaling through modulation of intracellular calcium levels. Decreased activity of CaMKII can lead to an altered cellular response to OR2A12 activation. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine inhibits PKC, which can be activated downstream of G protein-coupled receptors like OR2A12. Inhibition of PKC results in decreased OR2A12-mediated responses. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Pertussis toxin ADP-ribosylates and inactivates Gi/o proteins, which are one of the G protein subtypes that OR2A12 can couple to. This results in decreased OR2A12 signaling. | ||||||
Paroxetine | 61869-08-7 | sc-507527 | 1 g | $180.00 | ||
Paroxetine inhibits G protein-coupled receptor kinases (GRKs), which are responsible for phosphorylating activated receptors like OR2A12, leading to receptor desensitization. Inhibition of GRKs results in altered OR2A12 signaling dynamics. | ||||||
ESI-09 | 263707-16-0 | sc-507491 | 5 mg | $230.00 | ||
ESI-09 inhibits Epac, which is a cAMP-regulated guanine nucleotide exchange factor involved in the signaling pathways of receptors such as OR2A12. By inhibiting Epac, the downstream effects of OR2A12 activation are reduced. | ||||||